Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …

Conventional chemotherapy treatment for cancer tends to show severe systemic toxicities
like hair loss (alopecia), anemia, diarrhea, edema and loss of appetite …

Radiosynovectomy is a technique used to decrease inflammation of the synovial tissue by
intraarticular injection of a β-emitting radionuclide, such as 177 Lu, which is suitable for …

The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging
and therapy of prostate cancer using bombesin peptides that bind to the receptor with high …

The gastrin-releasing peptide receptor (GRPr) is overexpressed in> 75% of breast cancers.
177 Lu-Bombesin (177 Lu-BN) has demonstrated the ability to target GRPr and facilitate …

177Lu‐labeled nanoparticles conjugated to biomolecules have been proposed as a new
class of theranostic radiopharmaceuticals. The aim of this research was to synthesize 177Lu …

Despite efforts, cancer is still one of the leading causes of morbidity and mortality worldwide,
with approximately 14 million new cases and 8.2 million cancer-related deaths each year …

The peptide-receptor radionuclide therapy (PRRT) is a successful approach for selectively
delivering radiation within tumor sites through specific recognition of radiolabeled peptides …

The integration of fluorescence and plasmonic properties into one molecule is of importance
in developing multifunctional imaging and therapy nanoprobes. The aim of this research …

The gastrin-releasing peptide receptor (GRPR) is known to be overexpressed in breast
cancer, making it a promising target for both imaging and therapy within a theranostic …